Your browser is no longer supported. Please, upgrade your browser.
Agios Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-4.93 Insider Own11.33% Shs Outstand69.14M Perf Week-0.35%
Market Cap3.22B Forward P/E- EPS next Y-5.66 Insider Trans0.00% Shs Float61.42M Perf Month32.80%
Income-332.10M PEG- EPS next Q-1.33 Inst Own92.60% Short Float8.85% Perf Quarter29.85%
Sales194.60M P/S16.55 EPS this Y-13.80% Inst Trans-4.47% Short Ratio6.51 Perf Half Y-14.80%
Book/sh6.95 P/B6.57 EPS next Y-21.20% ROA-37.20% Target Price64.20 Perf Year-11.41%
Cash/sh8.59 P/C5.32 EPS next 5Y40.00% ROE-57.60% 52W Range27.77 - 56.74 Perf YTD5.40%
Dividend- P/FCF- EPS past 5Y-34.00% ROI- 52W High-19.52% Beta1.65
Dividend %- Quick Ratio9.40 Sales past 5Y12.50% Gross Margin98.90% 52W Low64.43% ATR2.42
Employees536 Current Ratio9.60 Sales Q/Q33.50% Oper. Margin- RSI (14)59.30 Volatility4.81% 4.97%
OptionableYes Debt/Eq0.00 EPS Q/Q20.70% Profit Margin- Rel Volume1.72 Prev Close45.95
ShortableYes LT Debt/Eq0.00 EarningsNov 05 BMO Payout- Avg Volume834.35K Price45.67
Recom1.70 SMA205.99% SMA508.87% SMA2005.43% Volume1,433,452 Change-0.61%
Oct-22-20Upgrade Barclays Equal Weight → Overweight $46
Mar-04-20Initiated Barclays Equal Weight $50
Nov-26-19Initiated Cantor Fitzgerald Overweight $64
Sep-23-19Upgrade Guggenheim Neutral → Buy $55
May-23-19Resumed Goldman Neutral $55
Feb-15-19Upgrade SVB Leerink Mkt Perform → Outperform $80
Sep-25-18Initiated Leerink Partners Mkt Perform
May-23-18Initiated Citigroup Buy $117
Apr-11-18Reiterated Credit Suisse Outperform $80 → $95
Feb-15-18Reiterated SunTrust Buy $80 → $101
Feb-15-18Reiterated Needham Buy $72 → $86
Sep-15-17Initiated RBC Capital Mkts Outperform $78
Aug-10-17Reiterated Needham Buy $54 → $72
Aug-08-17Reiterated SunTrust Buy $68 → $80
Aug-02-17Upgrade Leerink Partners Mkt Perform → Outperform $80
Jun-26-17Downgrade Janney Buy → Neutral
Jan-17-17Upgrade Oppenheimer Perform → Outperform
Oct-24-16Initiated Needham Buy $60
Jun-13-16Upgrade JP Morgan Neutral → Overweight
May-18-16Reiterated SunTrust Buy $57 → $65
Jan-17-21 10:00AM  
Jan-11-21 07:00AM  
Jan-05-21 07:00AM  
Dec-23-20 08:30AM  
Dec-22-20 10:22AM  
Dec-21-20 04:25PM  
Dec-20-20 05:16PM  
Dec-07-20 04:30PM  
Dec-05-20 11:31AM  
Dec-04-20 08:00AM  
Dec-02-20 10:55AM  
Dec-01-20 07:00AM  
Nov-30-20 07:00AM  
Nov-25-20 07:00AM  
Nov-20-20 10:14AM  
Nov-13-20 10:57AM  
Nov-12-20 04:30PM  
Nov-07-20 07:16AM  
Nov-06-20 11:20AM  
Nov-05-20 09:00PM  
Nov-04-20 11:46AM  
Oct-30-20 06:29AM  
Oct-29-20 04:01PM  
Oct-22-20 12:34PM  
Oct-19-20 12:06PM  
Oct-16-20 04:01PM  
Oct-05-20 12:00PM  
Sep-21-20 07:00AM  
Sep-16-20 05:10PM  
Sep-08-20 04:01PM  
Sep-05-20 07:27AM  
Aug-31-20 06:35AM  
Aug-29-20 11:31AM  
Aug-27-20 07:00AM  
Aug-06-20 07:00AM  
Jul-30-20 10:01PM  
Jul-23-20 12:32PM  
Jul-17-20 12:46PM  
Jul-16-20 07:01AM  
Jul-10-20 07:16AM  
Jul-02-20 06:08AM  
Jun-19-20 01:21AM  
Jun-18-20 12:00PM  
Jun-17-20 04:01PM  
Jun-12-20 04:23PM  
Jun-10-20 11:30AM  
Jun-09-20 11:29AM  
Jun-08-20 04:01PM  
May-30-20 11:31AM  
May-29-20 08:00AM  
May-28-20 11:56AM  
May-21-20 11:30AM  
May-19-20 07:00AM  
May-14-20 09:41AM  
May-13-20 05:01PM  
May-12-20 06:00PM  
May-07-20 10:18AM  
May-03-20 08:14AM  
May-01-20 08:10AM  
Apr-30-20 09:05AM  
Apr-23-20 12:32PM  
Apr-16-20 07:00AM  
Apr-15-20 09:01AM  
Apr-14-20 04:57PM  
Mar-30-20 04:01PM  
Mar-27-20 03:50PM  
Mar-25-20 04:01PM  
Mar-24-20 01:08PM  
Mar-23-20 07:00AM  
Mar-14-20 11:30AM  
Mar-03-20 09:05AM  
Feb-19-20 07:59AM  
Feb-18-20 07:00AM  
Feb-14-20 11:04AM  
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Biller JonathanChief Financial OfficerDec 03Option Exercise0.005,753011,747Dec 07 06:21 PM
Alenson CarmanPrincipal Accounting OfficerSep 02Sale39.932509,983184Sep 04 04:24 PM
Bowden ChristopherChief Medical OfficerMay 20Option Exercise35.163,583125,97811,889May 21 05:05 PM
Bowden ChristopherChief Medical OfficerMay 20Sale50.013,583179,2008,306May 21 05:05 PM
Alenson CarmanPrincipal Accounting OfficerMar 02Sale47.3034516,319184Mar 04 05:08 PM
Alenson CarmanPrincipal Accounting OfficerFeb 26Sale47.1247222,241184Feb 28 04:17 PM
Alenson CarmanPrincipal Accounting OfficerFeb 20Sale53.372,427129,529184Feb 24 04:02 PM
Bowden ChristopherChief Medical OfficerFeb 13Option Exercise35.167,100249,6368,750Feb 18 04:05 PM
Bowden ChristopherChief Medical OfficerFeb 13Sale50.167,100356,1121,650Feb 18 04:05 PM
Bowden ChristopherChief Medical OfficerFeb 11Option Exercise35.1662121,8342,271Feb 13 04:21 PM
Bowden ChristopherChief Medical OfficerFeb 11Sale50.0262131,0631,650Feb 13 04:21 PM
Bowden ChristopherChief Medical OfficerFeb 05Option Exercise35.1635,4471,246,31737,097Feb 06 04:52 PM
Bowden ChristopherChief Medical OfficerFeb 04Option Exercise35.168,526299,77415,841Feb 06 04:52 PM
Bowden ChristopherChief Medical OfficerFeb 04Sale50.0849,6382,485,9891,650Feb 06 04:52 PM